Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

Zacks2023-11-24

Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2385678737?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2","is_english":true,"pubTime":"2023-11-24 00:03","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2385678737","market":"us","top_or_hot":-1,"title":"Freeline (FRLN) Shares Rise on Merger Agreement With Syncona","media":"Zacks","content":"<div>\n<p>Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per ...</p>\n\n<a href=\"https://finance.yahoo.com/news/freeline-frln-shares-rise-merger-160300908.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Freeline (FRLN) Shares Rise on Merger Agreement With Syncona</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFreeline (FRLN) Shares Rise on Merger Agreement With Syncona\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-24 00:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/freeline-frln-shares-rise-merger-160300908.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per ...</p>\n\n<a href=\"https://finance.yahoo.com/news/freeline-frln-shares-rise-merger-160300908.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/freeline-frln-shares-rise-merger-160300908.html","article_id":"2385678737","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2385678737","pubTimestamp":1700755380,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per the deal, Freeline is set to be acquired by Syncona in an all-cash transaction.The above transaction is expected to be closed in the first quarter of 2024, subject to approval by Freeline’s minority shareholders. Shares of Freeline were up 10.2% on Nov 22 following the announcement of the news.Per the acquisition agreement, Syncona will acquire all shares of Freeline for $6.50 per American Depositary Share  that it currently does not own. The price offered by Syncona represents a 51% premium over the closing price of Freeline’s shares as of Oct 18 and values the latter’s entire issued share capital at approximately $28.3 million.In the past 60 days, Ligand Pharmaceuticals’ earnings per share estimates for 2023 have improved from $4.98 to $5.33. During the same period,","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LGND":"Ligand Pharmaceuticals Inc.","PBYI":"Puma Biotechnology Inc","CTMX":"CytomX","BK4139":"生物科技","FRLN":"Freeline Therapeutics Holdings plc"},"translate_title":"Freeline（FRLN）股价因与Syncona达成合并协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"FRLN":1,"LGND":1,"PBYI":0.9},"content_text":"Freeline Therapeutics Holdings plc FRLN, a clinical-stage biotechnology company, announced that it has entered into a definitive agreement with United Kingdom-based portfolio company Syncona Ltd. Per the deal, Freeline is set to be acquired by Syncona in an all-cash transaction.\nThe above transaction is expected to be closed in the first quarter of 2024, subject to approval by Freeline’s minority shareholders. Shares of Freeline were up 10.2% on Nov 22 following the announcement of the news.\nPer the acquisition agreement, Syncona will acquire all shares of Freeline for $6.50 per American Depositary Share (ADS) that it currently does not own. The price offered by Syncona represents a 51% premium over the closing price of Freeline’s shares as of Oct 18 and values the latter’s entire issued share capital at approximately $28.3 million.\nAlso, as part of the merger agreement, Freeline will receive up to $15 million in secured convertible debt financing from Syncona. With this financing, Freeline is looking to fund its operations and continue the advancement of FLT201, its gene therapy candidate till the acquisition transaction is completed.\nFreeline is currently evaluating FLT201 in the phase I/II GALILEO-1 study for the treatment of patients with Gaucher disease type 1. The company is planning to use the proceeds from the above mentioned debt financing for a potential registrational study on FLT201 and move ahead with its GBA1-linked Parkinson’s disease research program.\nShares of Freeline have lost 18.5% in the year-to-date period compared with the industry’s decline of 23.7%.\nImage Source: Zacks Investment Research\nUpon the completion of the above acquisition, Freeline will become a privately held, wholly-owned company of Syncona, and its ADS will not be trading any further on the Nasdaq stock exchange.\nWe note that Freeline’s independent directors unanimously recommended that the above acquisition transaction is in the best interest of the company and is likely to create significant value for its shareholders.\nZacks Rank & Other Stocks to Consider\nFreeline currently carries a Zacks Rank #2 (Buy).\nSome other top-ranked stocks in the healthcare sector are CytomX Therapeutics, Inc. CTMX, Ligand Pharmaceuticals Incorporated LGND and Puma Biotechnology, Inc. PBYI, sporting a Zacks Rank #1 (Strong Buy) each.You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2023 loss per share have narrowed from 37 cents to 10 cents. Meanwhile, loss per share estimates for 2024 have narrowed from 51 cents to 22 cents. Year to date, shares of CTMX have lost 18.4%.\nEarnings of CytomX Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. CTMX delivered a four-quarter average earnings surprise of 45.44%.\nIn the past 60 days, Ligand Pharmaceuticals’ earnings per share estimates for 2023 have improved from $4.98 to $5.33. During the same period, earnings per share estimates for 2024 have moved up from $4.26 to $4.64. Year to date, shares of LGND have decreased 12.5%.\nEarnings of Ligand Pharmaceuticals beat estimates in each of the trailing four quarters. On average, LGND came up with a four-quarter earnings surprise of 67.19%.\nIn the past 60 days, estimates for Puma Biotechnology’s 2023 earnings per share have improved from 67 cents to 72 cents. During the same period, earnings per share estimates for 2024 have moved up from 55 cents to 62 cents. Year to date, shares of PBYI have lost 9%.\nEarnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nPuma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nFreeline Therapeutics Holdings PLC Sponsored ADR (FRLN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2385678737"}